HCV Developing World Strategy
Amadou Diarra, Head of Global Policy, Advocacy & Government Affairs
recognizes the significant public health challenge that hepatitis C virus (HCV) presents worldwide, including the substantial burden of the disease in the developing world. With more than 80% of the global HCV patient population living in low- and middle-income countries, there is great need for hepatitis C treatment options in these countries. The significant challenges facing many of these countries are not homogeneous and beyond the reach of any one stakeholder to unilaterally address. A particular need exists for governments, non-governmental organizations, civil society and industry to form coalitions to address the challenges.
Bristol-Myers Squibb is continuing to strengthen our efforts to enable global access to Daklinza (daclatasvir). We are employing multiple approaches including tiered pricing in low- and middle-income countries, supplemented by a direct-import program in countries where we do not have plans to commercialize Daklinza. Our tiered pricing model for Daklinza takes into consideration several factors, including countries’ economic development and burden of disease, as well as the commitment of the government to holistically address hepatitis C, including treatment and care. The lowest pricing tier applies to all low-income and least developed countries.
Of significance, we have entered into the first-ever licensing agreement for a hepatitis C medicine with the Medicines Patent Pool (MPP), which will provide a royalty-free license for daclatasvir (Daklinza) in a territory of 112 countries across the globe (see list at right). Nearly two-thirds of all hepatitis C patients in low- and middle-income countries currently reside in the licensing territory, and in developing countries that are not currently included in this footprint, BMS plans to work with authorities and other stakeholders to enable access to Daklinza using other approaches.